Literature DB >> 31656791

Five-year overall survival of pembrolizumab in advanced non-small cell lung cancer: another step from care to cure?

Paolo Bironzo1, Francesco Passiglia1, Silvia Novello1.   

Abstract

Entities:  

Year:  2019        PMID: 31656791      PMCID: PMC6789333          DOI: 10.21037/atm.2019.08.91

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  10 in total

1.  Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Authors:  Leena Gandhi; Delvys Rodríguez-Abreu; Shirish Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J Hochmair; Steven F Powell; Susanna Y-S Cheng; Helge G Bischoff; Nir Peled; Francesco Grossi; Ross R Jennens; Martin Reck; Rina Hui; Edward B Garon; Michael Boyer; Belén Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M Catherine Pietanza; Marina C Garassino
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

3.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

4.  STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

Authors:  Ferdinandos Skoulidis; Michael E Goldberg; Danielle M Greenawalt; Matthew D Hellmann; Mark M Awad; Justin F Gainor; Alexa B Schrock; Ryan J Hartmaier; Sally E Trabucco; Laurie Gay; Siraj M Ali; Julia A Elvin; Gaurav Singal; Jeffrey S Ross; David Fabrizio; Peter M Szabo; Han Chang; Ariella Sasson; Sujaya Srinivasan; Stefan Kirov; Joseph Szustakowski; Patrik Vitazka; Robin Edwards; Jose A Bufill; Neelesh Sharma; Sai-Hong I Ou; Nir Peled; David R Spigel; Hira Rizvi; Elizabeth Jimenez Aguilar; Brett W Carter; Jeremy Erasmus; Darragh F Halpenny; Andrew J Plodkowski; Niamh M Long; Mizuki Nishino; Warren L Denning; Ana Galan-Cobo; Haifa Hamdi; Taghreed Hirz; Pan Tong; Jing Wang; Jaime Rodriguez-Canales; Pamela A Villalobos; Edwin R Parra; Neda Kalhor; Lynette M Sholl; Jennifer L Sauter; Achim A Jungbluth; Mari Mino-Kenudson; Roxana Azimi; Yasir Y Elamin; Jianjun Zhang; Giulia C Leonardi; Fei Jiang; Kwok-Kin Wong; J Jack Lee; Vassiliki A Papadimitrakopoulou; Ignacio I Wistuba; Vincent A Miller; Garrett M Frampton; Jedd D Wolchok; Alice T Shaw; Pasi A Jänne; Philip J Stephens; Charles M Rudin; William J Geese; Lee A Albacker; John V Heymach
Journal:  Cancer Discov       Date:  2018-05-17       Impact factor: 39.397

5.  Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.

Authors:  Tony S K Mok; Yi-Long Wu; Iveta Kudaba; Dariusz M Kowalski; Byoung Chul Cho; Hande Z Turna; Gilberto Castro; Vichien Srimuninnimit; Konstantin K Laktionov; Igor Bondarenko; Kaoru Kubota; Gregory M Lubiniecki; Jin Zhang; Debra Kush; Gilberto Lopes
Journal:  Lancet       Date:  2019-04-04       Impact factor: 79.321

6.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.

Authors:  Laura Mezquita; Edouard Auclin; Roberto Ferrara; Melinda Charrier; Jordi Remon; David Planchard; Santiago Ponce; Luis Paz Ares; Laura Leroy; Clarisse Audigier-Valette; Enriqueta Felip; Jorge Zerón-Medina; Pilar Garrido; Solenn Brosseau; Gérard Zalcman; Julien Mazieres; Caroline Caramela; Jihene Lahmar; Julien Adam; Nathalie Chaput; Jean Charles Soria; Benjamin Besse
Journal:  JAMA Oncol       Date:  2018-03-01       Impact factor: 31.777

7.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.

Authors:  J Mazieres; A Drilon; A Lusque; L Mhanna; A B Cortot; L Mezquita; A A Thai; C Mascaux; S Couraud; R Veillon; M Van den Heuvel; J Neal; N Peled; M Früh; T L Ng; V Gounant; S Popat; J Diebold; J Sabari; V W Zhu; S I Rothschild; P Bironzo; A Martinez-Marti; A Curioni-Fontecedro; R Rosell; M Lattuca-Truc; M Wiesweg; B Besse; B Solomon; F Barlesi; R D Schouten; H Wakelee; D R Camidge; G Zalcman; S Novello; S I Ou; J Milia; O Gautschi
Journal:  Ann Oncol       Date:  2019-08-01       Impact factor: 32.976

8.  Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.

Authors:  Edward B Garon; Matthew D Hellmann; Naiyer A Rizvi; Enric Carcereny; Natasha B Leighl; Myung-Ju Ahn; Joseph Paul Eder; Ani S Balmanoukian; Charu Aggarwal; Leora Horn; Amita Patnaik; Matthew Gubens; Suresh S Ramalingam; Enriqueta Felip; Jonathan W Goldman; Cathie Scalzo; Erin Jensen; Debra A Kush; Rina Hui
Journal:  J Clin Oncol       Date:  2019-06-02       Impact factor: 44.544

9.  Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Alexander Drilon; Jedd D Wolchok; Richard D Carvajal; M Brent McHenry; Fareeda Hosein; Christopher T Harbison; Joseph F Grosso; Mario Sznol
Journal:  JAMA Oncol       Date:  2019-10-01       Impact factor: 31.777

10.  Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors:  Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal:  N Engl J Med       Date:  2018-06-04       Impact factor: 91.245

  10 in total
  4 in total

1.  Is there hope in improving 5-year overall survival?-review of 5-year overall survival data from KEYNOTE-001.

Authors:  Wisdom Akingbemi; Edward Garon
Journal:  Ann Transl Med       Date:  2020-06

2.  Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review.

Authors:  Alexander Vartanov; Aditi Kalotra; Jasmine Varughese; Shovendra Gautam; Sean Kandel; Wylie Hosmer
Journal:  Respir Med Case Rep       Date:  2021-03-18

3.  Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients.

Authors:  Xinyu Chen; Qing Bu; Xuexin Yan; Ye Li; Qian Yu; Haiping Zheng; Liang Zhao; Yanwu Zeng; Leilei Lu; Dong Lan; Jie Ma
Journal:  J Oncol       Date:  2020-12-08       Impact factor: 4.375

4.  Identification and validation of HELLS (Helicase, Lymphoid-Specific) and ICAM1 (Intercellular adhesion molecule 1) as potential diagnostic biomarkers of lung cancer.

Authors:  Wei Zhu; Lin Lin Li; Yiyan Songyang; Zhan Shi; Dejia Li
Journal:  PeerJ       Date:  2020-03-09       Impact factor: 2.984

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.